Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04397718 · ClinicalTrials.gov registry record · Phase 2
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT04397718: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT04397718 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04397718, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
Primary Outcome
Number of Patients who died, had a ongoing need for hospitalization, or was placed on mechanical ventilation at Day 15.
Interventions
- OTHER Saline
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-06-08 |
| Phase | Phase 2 |
What the finished NCT04397718 record still lists
NCT04397718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04397718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04397718 about?
NCT04397718 is a clinical study titled "Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization". The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
What is the current status of trial NCT04397718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2020-07-06. Estimated completion is 2021-06-08.
What interventions are being tested in trial NCT04397718?
The interventions under investigation include: Saline (OTHER), Degarelix (DRUG).
Who is sponsoring clinical trial NCT04397718?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04397718's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI